Rathbones Group PLC Adaptimmune Therapeutics PLC Transaction History

Rathbones Group PLC

$19 Billion
Q3 2024

A detailed history of Rathbones Group PLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rathbones Group PLC holds 432,818 shares of ADAP stock, worth $259,690. This represents 0.0% of its overall portfolio holdings.

Number of Shares

432,818

Previous 432,818 -0.0%

Holding current value

$259,690

Previous $424,000 3.07%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$3.5 - $5.68 $360 - $585	-103 Reduced 0.02%	432,818 $1.62 Million
Q3 2020 Nov 13, 2020	SELL	$7.66 - $10.78 $76,600 - $107,800	-10,000 Reduced 2.26%	432,921 $3.46 Million
Q2 2020 Aug 07, 2020	BUY	$2.58 - $12.1 $113,695 - $533,222	44,068 Added 11.05%	442,921 $4.43 Million
Q1 2020 May 04, 2020	SELL	$1.2 - $4.52 $364,466 - $1.37 Million	-303,722 Reduced 43.23%	398,853 $1.09 Million
Q3 2019 Nov 13, 2019	SELL	$1.43 - $3.81 $2,712 - $7,227	-1,897 Reduced 0.27%	702,575 $1.06 Million
Q2 2019 Aug 12, 2019	BUY	$3.23 - $5.41 $1.35 Million - $2.27 Million	418,750 Added 146.56%	704,472 $2.83 Million
Q1 2019 May 09, 2019	BUY	$3.63 - $6.06 $226,119 - $377,489	62,292 Added 27.88%	285,722 $1.23 Million
Q3 2018 Oct 12, 2018	SELL	$8.27 - $13.56 $165,400 - $271,200	-20,000 Reduced 8.22%	223,430 $3.03 Million
Q1 2018 Apr 06, 2018	SELL	$7.1 - $11.56 $493,450 - $803,420	-69,500 Reduced 22.21%	243,430 $2.73 Million
Q4 2017 Jan 24, 2018	SELL	$6.68 - $8.74 $54,241 - $70,968	-8,120 Reduced 2.53%	312,930 $2.09 Million
Q3 2017 Oct 24, 2017	BUY	$4.93 - $8.93 $1.58 Million - $2.87 Million	321,050	321,050 $2.63 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

145M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.

Account

Rathbones Group PLC Adaptimmune Therapeutics PLC Transaction History